MA H2203

Department of Public Health must develop a "Psilocybin-Assisted Therapy Program" pilot to provide psilocybin services for adults 21+ with PTSD, end-of-life distress, depression, or other specified conditions

Psilocybin therapy must be delivered through FDA-approved pathways in controlled, community-based settings supervised by university researchers experienced in psychedelic clinical trials, with preference given to Massachusetts public universities

Participating universities are responsible for protocol design, institutional review board approvals, training facilitators, and data collection, while maintaining strict protocols for participant screening, informed consent, and dosing

Department must submit peer-reviewed annual reports beginning 12 months after enactment to legislative committees, including analysis of pilot efficacy and feasibility of MassHealth coverage for psilocybin-assisted therapy

Pilot program duration is minimum two years, funded through appropriations, grants, donations, or trust funds, with effective date of January 1, 2026